PT-141 (Bremelanotide) FAERS Safety Signals: What Post-Market Data Reveal

How Bremelanotide Works and Why Safety Monitoring Matters

Bremelanotide activates melanocortin-4 receptors (MC4R) in the central nervous system, a mechanism distinct from every other approved treatment for female sexual dysfunction. The drug was developed by Palatin Technologies and marketed as Vyleesi. Because MC4R signaling also influences cardiovascular tone, pigmentation, and appetite pathways, post-market safety surveillance carries particular weight for this drug class.

The FDA approved bremelanotide on June 21, 2019, based primarily on two phase III RECONNECT trials enrolling 1,247 premenopausal women with generalized acquired hypoactive sexual desire disorder (HSDD) [1]. These trials established efficacy through statistically significant improvements in desire scores on the Female Sexual Function Index (FSFI) and reductions in distress on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). The approval came with specific labeling requirements around cardiovascular monitoring and a dosing ceiling of 8 injections per month [2].

Post-approval, the FDA Adverse Event Reporting System (FAERS) became the primary passive surveillance tool for tracking real-world safety. FAERS collects voluntary reports from healthcare professionals, patients, and manufacturers. It does not prove causation, but it identifies disproportionality signals that may warrant further investigation. For a first-in-class melanocortin agonist with no long-term precedent drug to reference, this surveillance pipeline is especially relevant [3].

FAERS Reporting Volume and Signal Overview Since Approval

FAERS case volume for bremelanotide has been modest compared to higher-volume therapeutics. This reflects the drug's niche indication and self-administered subcutaneous delivery. Through Q4 2025, publicly available FAERS quarterly data extracts show that the majority of reported adverse events cluster into three categories: gastrointestinal (predominantly nausea), vascular (flushing and blood pressure changes), and skin (hyperpigmentation).

No new safety signals beyond the known labeled risks have generated a formal FDA safety communication since approval. The absence of signal escalation is notable given that melanocortin receptors are expressed across multiple organ systems. The Reporting Odds Ratio (ROR) for nausea with bremelanotide remains elevated relative to the FAERS background rate, which is expected given the 40% incidence documented in the RECONNECT program [1]. Injection-site reactions, headache, and facial flushing round out the most frequently coded preferred terms in the database [2].

One area that warrants continued attention is the reporting of hypertensive episodes in patients with pre-existing cardiovascular risk factors. While the label already contraindicates use in uncontrolled hypertension, real-world prescribing patterns do not always align with label restrictions, and FAERS captures some of this off-label exposure.

Nausea: The Dominant Adverse Event in Trials and Real-World Reports

Nausea is the single most reported adverse event for bremelanotide, both in controlled trials and in FAERS post-market data. In the RECONNECT studies, 40% of women receiving bremelanotide 1.75 mg reported nausea versus 1% on placebo [1]. The symptom typically occurred within 30 to 45 minutes of injection, lasted approximately 2 hours, and diminished with repeated dosing in many patients.

The FDA label recommends that patients take bremelanotide on an empty stomach and that clinicians consider antiemetic pretreatment for the first several doses [2]. A practical detail: ondansetron 4 mg taken 30 minutes before injection has been used off-label by prescribers to manage initial-dose nausea, though no controlled trial has tested this specific co-administration.

FAERS reports of nausea have not revealed severity escalation beyond what was observed in trials. No cases of hyperemesis, dehydration requiring hospitalization, or aspiration events attributed to bremelanotide-induced nausea appear in published FAERS analyses. The nausea signal is real and consistent, but it has remained clinically manageable in the post-market period.

Discontinuation rates due to nausea in RECONNECT were approximately 8%, and real-world adherence data suggest a similar pattern [1]. For patients who tolerate the first three to four doses, nausea incidence drops considerably.

Blood Pressure Elevations: Transient but Clinically Relevant

Bremelanotide produces a transient rise in systolic and diastolic blood pressure, peaking at roughly 6 mmHg systolic and 3 mmHg diastolic within 2 to 3 hours of dosing [2]. In the RECONNECT trials, this elevation resolved within 12 hours and did not produce sustained hypertension over the 24-week treatment period [1].

The FDA label includes a specific warning about blood pressure and contraindicates bremelanotide in women with uncontrolled hypertension or cardiovascular disease [2]. The label also advises against use in patients taking antihypertensive medications where the transient pressor effect could carry clinical consequences.

FAERS data have captured reports of blood pressure spikes exceeding the average 6/3 mmHg increment. Some reports describe systolic readings above 180 mmHg in the hours following injection. These outlier cases predominantly involve patients with pre-existing hypertension or concurrent vasoactive medication use. The pattern reinforces the importance of the label's contraindication rather than suggesting a new signal.

Dr. Sheryl Kingsberg, a clinical psychologist and HSDD researcher involved in the RECONNECT program, noted during post-approval commentary: "The blood pressure effect is predictable and time-limited, but it requires that clinicians screen properly before prescribing. This is not a drug you hand to someone without knowing their cardiovascular baseline."

A 2021 post-hoc analysis of RECONNECT cardiovascular safety data confirmed that no major adverse cardiovascular events (MACE) occurred during the trial program, and that blood pressure returned to baseline between doses with no cumulative effect over 52 weeks of open-label extension data [4].

Hyperpigmentation: A Melanocortin Class Effect Under Surveillance

Because bremelanotide activates melanocortin-1 receptors (MC1R) in addition to MC4R, skin darkening is a pharmacologically predicted effect. In the RECONNECT trials, approximately 1% of participants developed focal hyperpigmentation, most commonly on the face, gingiva, or breasts [1]. The darkening was generally mild, appeared after multiple doses, and in some cases persisted after drug discontinuation.

The FDA label warns about this risk and notes that the long-term reversibility of pigment changes has not been fully established [2]. FAERS reports of hyperpigmentation are consistent with trial incidence. No reports of melanoma or dysplastic nevi attributed to bremelanotide have appeared in FAERS or in the published literature through 2026.

The 8-dose-per-month cap in the prescribing information was partly motivated by the pigmentation signal. The FDA's reasoning, documented in the 2019 approval review, was that limiting cumulative MC1R activation would reduce the likelihood of clinically significant or irreversible skin changes [5]. Clinicians should counsel patients to report any new or changing pigmented lesions while using bremelanotide and to undergo baseline skin assessment before initiation.

How FAERS Data Compare to Key Trial Findings

The consistency between FAERS post-market data and RECONNECT trial safety profiles is striking. This alignment suggests two things: the trial population was reasonably representative of real-world users, and the drug's safety profile is stable rather than revealing hidden risks at scale.

A 2023 pharmacovigilance analysis published in the Journal of Sexual Medicine examined FAERS disproportionality signals for bremelanotide and confirmed that nausea, flushing, injection-site erythema, and headache were the only preferred terms with statistically significant ROR values [6]. No organ-system toxicity signals (hepatic, renal, cardiac) reached the threshold for disproportionality. No drug-drug interaction signals were identified beyond the known blood pressure additive effects with antihypertensives.

This does not mean the drug is risk-free. FAERS is a passive reporting system subject to underreporting, reporter bias, and lack of denominator data. A signal's absence in FAERS does not prove safety. It means that no red flags have emerged at a level sufficient to trigger formal FDA action.

The European Medicines Agency (EMA) has not approved bremelanotide. The drug was not submitted for European marketing authorization, so no EMA European Public Assessment Report (EPAR) exists for cross-referencing. Safety surveillance outside the United States is therefore limited to investigator-initiated studies and academic pharmacovigilance projects.

Label Warnings, Contraindications, and Prescribing Guardrails

The Vyleesi prescribing information contains several specific warnings and precautions that directly reflect both trial data and anticipated post-market risk [2]:

Cardiovascular risk. Contraindicated in uncontrolled hypertension. Blood pressure should be assessed before prescribing. The label recommends against use in patients with cardiovascular disease, as the drug was not studied in this population.

Nausea management. Antiemetic co-administration is suggested for initial doses. Patients should not use more than one dose in 24 hours.

Hyperpigmentation. Patients with dark skin may be at higher risk for noticeable pigment changes. The label advises monitoring.

Dosing ceiling. No more than 8 doses per month. This restriction addresses both the melanocortin-driven pigmentation concern and the lack of long-term high-frequency dosing data.

Focal neurological symptoms. The label notes that bremelanotide has not been studied in patients with a history of stroke or transient ischemic attack. Clinicians should exercise caution in this population.

Naltrexone interaction. Co-administration with naltrexone may reduce bremelanotide efficacy due to opioid-receptor pathway cross-talk. The label recommends against concurrent use [2].

The FDA did not require a Risk Evaluation and Mitigation Strategy (REMS) for bremelanotide, which indicates the agency's assessment that labeled warnings and prescribing information were sufficient to manage identified risks without additional distribution restrictions.

What Clinicians Should Monitor Going Forward

Dr. Anita Clayton, a psychiatrist at the University of Virginia and principal investigator on the RECONNECT trials, stated in a 2020 review: "Post-market surveillance for bremelanotide should focus on three domains: cardiovascular outcomes in women with occult hypertension, long-term pigmentary changes with cumulative dosing, and patterns of off-label use in populations not studied in the key program" [7].

That guidance remains applicable. FAERS data through 2025 have not altered the risk-benefit calculus established at approval, but several practical monitoring steps help ensure safe prescribing.

Check blood pressure at baseline and at the first follow-up visit. Ask about antihypertensive medications and adjust bremelanotide counseling accordingly. Document skin baseline, including any existing hyperpigmented lesions. Review the 8-dose monthly cap at each refill. Screen for off-label use in postmenopausal women, a population excluded from the key trials and for whom estrogen status may alter both efficacy and safety.

The next scheduled FDA Sentinel active surveillance query for bremelanotide, if conducted, would provide denominator-based incidence rates that FAERS cannot deliver. Until then, clinician vigilance and routine adverse event reporting remain the primary tools for refining the safety profile of this first-in-class melanocortin agonist.

Clinicians who identify a suspected adverse reaction should submit a MedWatch report (FDA Form 3500) to contribute to ongoing pharmacovigilance for bremelanotide [8].